Tenaya Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
30/07/2025 21:02
Tenaya Therapeutics Inc TNYA.OQ TNYA.O is expected to show no change in quarterly revenue when it reports results on August 1 (estimated) for the period ending June 30 2025 ​LSEG's mean analyst estimate for Tenaya Therapeutics Inc is for a loss of 25 cents per share. The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. ​ Wall Street's median 12-month price target for Tenaya Therapeutics Inc is $5.00, about 85.9% above its last closing price of $0.70 Previous quarterly performance (using preferred earnings measure in US dollars). ​
| QUARTER ENDING | STARMINESMARTESTIMATEÂŪ | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
| Mar. 31 2025 | -0.19 | -0.19 | -0.24 | Missed | -26.3 |
| Dec. 31 2025 | -0.31 | -0.28 | Beat | 10 | |
| Sep. 30 2024 | -0.35 | -0.37 | -0.30 | Beat | 18.4​ |
| Jun. 30 2024 | -0.39 | -0.39 | -0.34 | Beat | 13.1 |
| ​​Mar. 31 2024 | -0.42 | -0.42 | -0.40 | Beat | 5.4 |
| Dec. 31 2023 | -0.50 | -0.44 | -0.40 | Beat | 8.8​ |
| Sep. 30 2023 | -0.47 | -0.47 | -0.39 | Beat | 17.5 |
| Jun. 30 2023 | -0.50 | -0.50 | -0.45 | Beat | 10.6 |
Recent news on Tenaya Therapeutics
See all newsBrief: Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms
Brief: Positive Interim Data From Cohorts 1 And 2 Of Tenaya's Ridge-1 Phase 1B/2 Clinical Trial Of TN-401
Tenaya Therapeutics Q1 net loss widens, misses analyst expectations
Brief: Tenaya Therapeutics Q1 Net Income USD -19.272 Million
Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027